Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers | Zendy

Erik Mogalian | Zendy; Luisa M. Stamm | Zendy; Anu Osinusi | Zendy; Diana M. Brainard | Zendy; Gong Shen | Zendy; Kah Hiing John Ling | Zendy; Anita Mathias | Zendy

Open Access

Drug–Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers

Author(s) -

Erik Mogalian,

Luisa M. Stamm,

Anu Osinusi,

Diana M. Brainard,

Gong Shen,

Kah Hiing John Ling,

Anita Mathias

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy201

Subject(s) - medicine , cobicistat , emtricitabine , pharmacology , dolutegravir , tenofovir alafenamide , tolerability , pharmacokinetics , ritonavir , efavirenz , darunavir , abacavir , atazanavir , population , sofosbuvir , hepatitis c virus , viral load , adverse effect , lamivudine , virology , hepatitis b virus , human immunodeficiency virus (hiv) , virus , ribavirin , environmental health , antiretroviral therapy

Combining antiviral regimens in the hepatitis C virus (HCV)/human immunodeficiency virus (HIV)-coinfected population can be complex as they share overlapping mechanisms for elimination that may result in drug interactions. The pharmacokinetics, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) with multiple antiretroviral (ARV) regimens were evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research